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Abstract: PURPOSE OF REVIEW Broadly neutralizing antibodies (bnAbs) are considered a key com-
ponent of an effective HIV-1 vaccine, but despite intensive efforts, induction of bnAbs by vaccination has
thus far not been possible. Potent bnAb activity is rare in natural infection and a deeper understanding
of factors that promote or limit bnAb evolution is critical to guide bnAb vaccine development. This
review reflects on recent key discoveries on correlates of bnAb development and discusses what further
insights are needed to move forward. RECENT FINDINGS An increasing number of parameters have
been implicated to influence bnAb development in natural infection. Most recent findings highlight a
range of immune factors linked with bnAb evolution. Novel approaches have brought exciting progress
in defining signatures of the viral envelope associated with bnAb activity. SUMMARY Focused efforts of
recent years have unraveled a multiply layered process of HIV-1 bnAb development. As it is understood
today, bnAb evolution can be triggered and influenced by a range of factors and several different path-
ways may exist how bnAb induction and maturation can occur. To capitalize on the gained knowledge,
future research needs to validate factors to identify independent drivers of bnAb induction to advance
vaccine design.
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Purpose of review
Broadly neutralizi‘‘ng antibodies (bnAbs) are considered a key component of an effective HIV-1 vaccine,
but despite intensive efforts, induction of bnAbs by vaccination has thus far not been possible. Potent bnAb
activity is rare in natural infection and a deeper understanding of factors that promote or limit bnAb
evolution is critical to guide bnAb vaccine development. This review reflects on recent key discoveries on
correlates of bnAb development and discusses what further insights are needed to move forward.
Recent findings
An increasing number of parameters have been implicated to influence bnAb development in natural
infection. Most recent findings highlight a range of immune factors linked with bnAb evolution. Novel
approaches have brought exciting progress in defining signatures of the viral envelope associated with
bnAb activity.
Summary
Focused efforts of recent years have unraveled a multiply layered process of HIV-1 bnAb development. As
it is understood today, bnAb evolution can be triggered and influenced by a range of factors and several
different pathways may exist how bnAb induction and maturation can occur. To capitalize on the gained
knowledge, future research needs to validate factors to identify independent drivers of bnAb induction to
advance vaccine design.
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INTRODUCTION
Neutralizing antibodies are a critical component of
licensed antiviral vaccines [1], but despite intensive
efforts, attempts to create an HIV-1 vaccine that
induces protective antibody responses failed thus
far. Neutralizing antibodies in natural HIV-1 infec-
tion are subject to rapid virus escape and predomi-
nantly target the autologous virus with limited
cross-neutralization activity [2,3]. The discovery of
broadly neutralizing antibodies (bnAbs) that neu-
tralize close to all HIV-1 strains across diverse sub-
types has revived HIV-1 vaccine development in the
past decade [4,5]. Today, bnAbs are at the center of
novel approaches considered in HIV-1 prevention,
therapy, cure, and vaccine development [6–9]. Pas-
sive immunization with bnAbs in animal models of
chronic HIV-1 infection and during analytic treat-
ment interruption (ATI) of HIV-1 infected individu-
als has underlined the potency of bnAbs [10–13].
bnAb treatment of HIV-1 infection has shown the
capacity to delay rebound during ATI, to decrease
viremia and virus set points in a notable number of
participants [10–12,14–16]. These capacities high-
light prospects for bnAb-based therapeutics [17–20].
Importantly, bnAbs prevent infection in animal
models by mucosal challenge [8,21–25] paving
the way for bnAb-based vaccines. Numerous vaccine
strategies are currently pursued and tested in animal
models [26,27], and large-scale human studies are
underway that probe the capacity of passively trans-
ferred bnAbs in preventing HIV-1 infection [28].
Despite many achievements in HIV vaccine
development, the ultimate goal, induction of bnAbs
by vaccination, has not been possible [5]. This has
called for intensive research efforts aiming to under-
stand how bnAbs develop in natural HIV-1
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infection. Induction of potent and broad neutraliz-
ing antibodies in HIV-1 infection is rare [29]. Knowl-
edge of the factors that restrict or promote bnAb
induction may thus provide crucial insight how the
limitations in evoking these responses by vaccina-
tion can be overcome. In recent years, a rapidly
increasing number of factors have been implicated
as determinants in the development of neutraliza-
tion breadth in natural infection (Fig. 1) but only a
fraction has been confirmed across different cohorts
as independently acting parameters [29–37].
Here, we report on current knowledge of the
determinants of bnAb induction with a specific
emphasis on the most recent reports, open ques-
tions, and goals for future research.
INFLUENCE OF HIV-1 INFECTION ON
BROADLY NEUTRALIZING ANTIBODIES
DEVELOPMENT
bnAb activity arises predominantly in viremic indi-
viduals after several years of infection [29,34,36,39]
suggesting thatprolongedexposure toviral antigen is
needed for bnAb induction. Not only the duration of
antigen exposure but also the amount of antigen
appears to play a role. A factormost frequently found
to positively influence neutralization breadth across
all cohorts is high viral load [29–37,40,41]. Never-
theless, although rates of bnAb activity are signifi-
cantly higher amongst individuals with high viral set
points, breadth can also develop (albeit at a lower
frequency) in HIV-1 controllers [31,40,42–45].
Hence, high antigenic burden promotes bnAb evo-
lution but certainly is not a strict requirement.
Continued replication drivesHIV-1 diversity and
this feature has been confirmed as independent
driver of bnAb induction [29,32,34–36]. Diversity
of envelope (Env) is particularly high reflecting the
effects of consecutive rounds of neutralizing anti-
body (nAb) attack, virus escape, and nAbmaturation
[46]. Studies deciphering the ontology of bnAb evo-
lution in individual donors have highlighted the
effects of this iterative process of bnAb maturation
and viral escape that gives rise to Env variants that
engage novel antibody germ lines and start a bnAb
lineage [47,48]. In which contexts Env diversity is
promoting bnAb evolution has however not conclu-
sively been defined. Although several studies
observed a positive effect [49] and some note links
between bnAb evolution and superinfection with
heterologous strains [39,50
&&
,51–53], the effect of
superinfection is not consistently reported across
cohorts and investigated cases [40,54
&&
,55,56]. A
recent report by Sheward et al. [54
&&
] shows that
consecutive exposure to heterologous Envs during
superinfection leads predominantly to de novo anti-
body responses. Although this still could lead to a
cumulative increase in polyclonal neutralization
activity as shownbyothers [57], the authors observed
no evolution of single bnAb specificities linked with
the investigated superinfection cases (N¼4).
Only for few individual bnAb donors epitope
specificity of the isolated bnAbs is known. The
majority of analyses available to date rely on data
of patient plasma for which bnAb specificity is either
inferred on the basis of their neutralization
KEY POINTS
 Define and validate factors that are linked with
bnAb induction.
 Define surrogate markers of bnAb induction to allow
early assessment of vaccine responses.
 Define Env signatures that promote bnAb induction.
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FIGURE 1. Determinants of bnAb induction suggested by studies reviewed here and in Subbaraman et al. [38].
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fingerprint (referred to commonly as delineation of
bnAb specificity) or not known. The impact of spe-
cific factors may thus also vary depending on the
epitope specificity of the elicited bnAb. We found
evidence that this may be the case for virus diversity
in a recent study by Kadelka et al. [58
&&
]. Analyzing
the Swiss 4.5K study for influence on neutralization
breadth [29] (N¼4484) and binding antibody
responses (N¼4281) [58
&&
], we defined diversity as
an independent driver of neutralization breadth.
However, when analyzed on the level of binding
antibodies, diversity proved to only promote gp120
responses and not gp41 membrane proximal
external region (MPER) antibody responses. Hence,
crucial epitope-dependent differences may exist. It
is plausible that antibody responses are not
impacted by overall Env diversity if the targeted
epitope region is highly conserved as it is the case
for the MPER. In consequence, this also effects the
interpretation of plasma neutralization breadth
data. Differential influence of factors, such as evi-
dent for diversity, will remain difficult to disentan-
gle as long as we cannot fully delineate plasma
neutralization activity (including thosewithmodest
breadth) and distinguish between breadth that
stems from additive polyclonal responses and
breadth that stems from true bnAb lineages.
DEFINING Env SIGNATURES THAT DRIVE
BROADLY NEUTRALIZING ANTIBODIES
EVOLUTION
Evidence is accumulating that qualitative differen-
ces amongst Env variants exist that strongly impact
and shape the bnAb response [29,59,60
&&
]. Genetic
subtypes of HIV-1 appear to differentially steer bnAb
responses. Potent CD4þ-binding site-targeting
bnAbs were reported to more frequently emerge in
subtype B infection [29,59], whereas V2-specific
bnAb responses emerge predominantly in non-B
infection [29]. Hence, Envs from different subtypes
must carry distinct signatures that promote one
bnAb specificity over the other that need to be
defined. However, even within these subtypes, anti-
body responses vary strongly and different bnAb
specificities emerge [29], highlighting the need to
define more distinct signatures that drive bnAb
development (see Doria-Rose et al., in this issue).
The overall Env diversity within and across patients
and subtypes, paired with the comparatively low
number of cases from which bnAbs have been iso-
lated and characterized, has thus far limited the
possibilities to define Env signatures that drive bnAb
evolution. Although a number of Env motifs, glyco-
sylation patterns, and variable loop length have
been implicated to be linked with breadth induction
and/or formation of specific bnAb specificities
[61
&
,62–65], transforming these into immunogens
that evoke bnAb responses was thus far not success-
ful. Considering the various distinct epitopes of the
identified bnAbs types, each bnAb specificity may
have its individual requirements on epitope compo-
sition and exposure on the immunogen. Decipher-
ing Env signatures of different bnAb types will
remain challenging but recently established, novel
approaches to delineate resistance patterns of bnAbs
are an important step into this direction. Applica-
tion of machine-learning techniques [66,67
&&
] and







have brought an unprecedented level of detail to
bnAb–Env signature analysis. In addition, novel
approaches to delineate neutralizing plasma anti-
body responses have been developed. Advanced
computational strategies to dissect polyclonal neu-
tralizing antibody activity [71
&
,72], epitope signa-
ture analysis of plasma responses by conventional
binding assays [73
&
], and advanced epitopemapping
of polyclonal antibody responses by electron
microscopy [74
&&
] have provided new insights and
avenues of research.
Definition of Env signatures that promote bnAb
activity has a high potential. Studying a large cohort
of transmission pairs defined by genetic linkage of
the infecting virus (N¼303 pairs), we recently
showed that transmitted viruses install a highly
similar antibody response in the recipient with cer-
tain viruses harboring the capacity to evoke a bnAb
response in both partners [60
&&
]. Identification and
characterization of virus strains that harbor a bnAb-
imprinting capacity are thus key to decipher
genetic, structural, and phenotypic features that
are linked to the unique immunogenicity of these
bnAb-imprinting virus strains.
INFLUENCE OF THE IMMUNE
ENVIRONMENT
bnAbs frequently harbor unique features such as
poly or autoreactivity, long HCDR3s, extraordinary
frequencies of V(D)J mutations, and framework
mutations [75–77] underlining that their evolution
needs to overcome host tolerance controls. Hence,
influencing these control mechanisms may foster
the generation of bnAbs in the context of vaccines
[78–80]. Evidence that bnAb evolution coincides
with a number of distinct immune conditions and
factors is increasing. Distinguishing amongst these
surrogate markers from true correlates will be an
important task for forthcoming studies.
A link between development of breadth and
poly/autoreactivity of antibodies has been noted
for long [81–86]. In line with an immune
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environment that promotes polyreactivity, some
studies observed a higher frequency of serum auto-
antibodies in individuals that mounted a bnAb
response [86,87]. As poly/autoreactive antibodies
are normally deselected during development
[75,76,80], bnAb evolution may thus benefit from
deficiencies in immune tolerance controls. Low lev-
els of T-regulatory cells, possibly enabling survival of
B-cell intermediateswithpotential for autoreactivity,
have been linked with neutralization breadth [86]. A
decline in overall CD4þ cell numbers, which could
also reflect a loss in T-regulatory cells, was suggested
by some studies to be linked with broad neutraliza-
tion [32,34,37,59]. Although conceptually very plau-
sible, these data need to be interpreted cautiously. A
link betweenbnAb evolution andCD4þ T-cell counts
was not universally observed [29,31,35,36,40]. As
viral load is a strong driver of bnAb activity and an
inverse association between CD4þ T-cell counts and
viral load [88] exists, dissection of confounding fac-
tors is essential but not all studies may have the size
with statistical power to disentangle effects (Fig. 2).
Thus, this need to dissect confounding influen-
ces does not only apply to the specific case of viral
load and CD4þ levels. In general, a validation of
proposed markers in larger cohorts is an urgent next
step in moving forward with the definition of bnAb
determinants (see key points).
Several factors implicated in germinal center
reaction have been defined as critical for bnAb evo-
lution.Higher levels of T-follicular helper (Tfh)CD4þ
cells early in infection have been observed in bnAb
inducers [79,86,91,94,95]. Elevated plasma levels of
CXCL13, a cytokine involved in B-cell migration to
the germinal center, and increased expression of
activation-induced deaminase, an enzyme crucial




Dubois et al., in this issue). Of note, higher frequency
of functional HIV-specific Tfh cells alongside a gen-
erally more tolerant immune environment in early
life have been suggested as possible causes of the
higher frequency of bnAb evolution observed in
pediatric HIV infection [97–101].
What prompts changes in immune environ-
ment that favor bnAb evolution is not clear. HIV-
1 infection causes widespread perturbations of
immune cells including B cells [102,103]. Recently,
impaired natural killer (NK) cell function and
RAB11FIP5 overexpression, which modulates NK
function, have been shown to be associated with
bnAb development in a cohort of 47 bnAb inducers
and 46 matched controls [90
&&
]. The effect was
attributed to a diminished ability of NK cells to
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FIGURE 2. Overview of conducted studies [29–37,40,45,58&&,78,79,86,89–93], their cohort size, and numbers of
variables tested. Bubble area is proportional to cohort size.
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Some bnAb specificities are restricted to a lim-
ited set of Ig heavy chain germ-line alleles [104].
Although thus far no overall difference in the immu-
noglobulin gene repertoire of bnAb inducers and
nonneutralizers has been observed [105], other
genetic determinants may exist that steer bnAb
evolution. Specific human leucocyte antigen alleles
and variants have been associated with bnAb activ-
ity in some cohorts [31,32,86,106,107]. In support
of a genetic influence, we recently reported that
individuals with black ethnicity more frequently
induce bnAb activity [29] and show enhanced
anti-Env-binding immunglobulin G1 (IgG1)
responses [58
&&
] compared with white study partic-
ipants of the Swiss 4.5K Study. As anti-Env IgG1
responses were generally elevated amongst bnAb
inducers compared with nonneutralizers, a link
between an IgG1-driven immune environment
and bnAb evolution seems to exist [58
&&
].
System serology studies have revealed multiple
aspects of the antibody response repertoire in vac-
cine recipients, HIV-1-infected nonneutralizers, and
bnAb inducers that highlight the differential regu-





,108–110]. Titer [32] and avidity [36] of
immunglobulin G-binding responses to Env-based
antigens can correlate with neutralization breadth.
Polyfunctional Fc effector profiles of anti-Env
responses are a component of viral control in natu-
ral HIV-1 infection [111–113] and distinguish
responses to different vaccine regimes [108–110].
Importantly, HIV-specific Fc effector function early
in infection was also shown to predict the develop-
ment of bnAbs [96
&&
] (see Ackerman et al., in this
issue). Thus, steering the immune response toward
certain Ig subclasses and/or Fc modifications may






Considering the wealth of factors implicated with
bnAb evolution, research efforts need tomove into a
next phase. Key points of future research (see key
points) need to be addressed. It will be critical to
dissect factors which are independent drivers of
bnAb induction from those that are surrogate
markers. This knowledge will aid vaccine develop-
ment immensely, allowing definition of factors with
relevance for immunization regimens. Identifica-
tion of surrogate markers that allow to reliably
predict bnAb evolution is similarly essential as these
could provide important tools for early assessment
of vaccine efficacy. Many of the data that we cur-
rently rely on are based on cohorts of a few dozen to
a few hundred individuals (Fig. 2; see also [38]).
Although these studies were instrumental inmaking
the initial discoveries, a critical next step will be the
validation of the implicated factors in larger cohorts
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